Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome
Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome
Read →
Infantile hemangiomas (IHs) are common benign tumors of childhood. IHs often regress satisfactorily without intervention, but a subset of IHs may lead to functional or cosmetic morbidity necessitating therapy. PHACE syndrome is characterize
article · Nov 2026
Available therapies for Gorham-Stout disease are not uniformly effective and often carry substantial morbidity. Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
Read →
Gorham-Stout disease is a life-threatening disorder often manifested by lymphatic malformation and osteolysis. Unfortunately, available therapies are not uniformly effective and often carry substantial morbidity. We report an 18-year-old ma
article · Nov 2026
Featured picks for families are being prepared — the summaries above are written for you.
Expert statements from the recordings in this collection.
Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
Gorham-Stout disease is a life-threatening disorder often manifested by lymphatic malformation and osteolysis.
Established practice
Available therapies for Gorham-Stout disease are not uniformly effective and often carry substantial morbidity.
Established practice
An 18-year-old male with Gorham-Stout disease manifested by lytic rib lesions and intractable pleural effusion responded dramatically to combination therapy with sirolimus and zoledronic acid after failing interferon therapy.
Cites published research
The combination of sirolimus and zoledronic acid has demonstrated synergism in preclinical cancer models.
Cites published research
Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome
Infantile hemangiomas are common benign tumors of childhood.
Established practice
Infantile hemangiomas often regress satisfactorily without intervention.
Established practice
A subset of infantile hemangiomas may lead to functional or cosmetic morbidity necessitating therapy.
Established practice
PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas.
Established practice
Treatment with sirolimus provided benefit with regression of the cutaneous infantile hemangioma in a patient with PHACE syndrome who failed conventional first-line therapies.
Cites published research
Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway.
Established practice
